Drugs / Durvalumumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05620771 | Nov 2022 → Jul 2040 expected | hepatocellular carcinoma | Northwestern University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Durvalumumab | “Patients will receive Durvalumumab + Tremelimumab if Bevacizumab is contraindicated.” NCT05620771 ↗ |